Effects of novel and conventional anti-cancer agents on human endothelial permeability: Influence of tumour secreted factors

Anticancer Research

Volumn 17, Issue 1 A, 1997, Pages 71-75

  Watts, Margaret E ^a   Woodcock, Michael ^a   Arnold, Stephanie ^a   Chaplin, David J ^a  

^a MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

Anti cancer agents; Combretastatin; Human umbilical vein endothelial cells; Melanoma cells; Permeability

Indexed keywords

ANTINEOPLASTIC AGENT; COMBRETASTATIN; F ACTIN; FLUOROURACIL; MELPHALAN; VASCULOTROPIN; VINBLASTINE;

ARTICLE; BLOOD VESSEL PERMEABILITY; COLLAPSE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOSKELETON; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; MELANOMA CELL; MEMBRANE FILTER; MONOLAYER CULTURE; PRIORITY JOURNAL; VASCULAR DISEASE; VASCULAR ENDOTHELIUM;

ANTINEOPLASTIC AGENTS; CAPILLARY PERMEABILITY; CYTOSKELETON; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; HUMANS; LYMPHOKINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0031057693     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Doll DC, Ringenberg OS and Yarbro JW:- Vascular toxicity associated with antineoplastic agents. J Clin Oncol 4: 1405-1417, 1986.
2. Ringenburg QS: Vascular toxicity. In: The Chemotherapy Source Book (Perry MC ed.). Baltimore, Williams and Wilkins, 680-688, 1992.
3. Connolly DT: Vascular permeability factor: A unique regulator of blood vessel function. J Cellular Biochem 47: 219-223, 1991.
4. Dvorak HF, Brown LF, Detmar M. and Dvorak AM: Vascular permeabitity factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Amer J Pathology 146: 1029-1039, 1995.
5. Watts ME and Woodcock M: Flavone acetic acid induced changes in human endothelial permeability: Potentiation by tumour-conditioned medium. European Journal of Cancer 28A: 1628-1632, 1992.
6. Smith KA, Thurston G and Murray JC: Systemic effects of FAA are enhanced by implanted tumours. Int J Rad Biol 60: 389-393, 1991.
7. Baguley BC, Holdaway KM, Thomsen LL, Zhuang L and Zwi LJ: Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: Evidence for a vascular mechanism. Eur J Cancer 27: 482-487, 1991.
8. Hill SA., Lonergan SJ, Denekamp J and Chaplin DJ: Vinca alkaloids: Antivascular effects in a murine tumour. Eur J Cancer 29A: 1320-1324, 1993.
9. Hill SA, Sampson LE and Chaplin DJ: Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid. Int J Cancer 63: 119-123 (1995).
10. Shasby DM, Shasby SS, Sullivan JM and Peach MJ: Role of endothelial cell cytoskeleton in control of endothelial permeability. Circulation Res 51: 657-661, 1982.
11. Schnittler H, Franke RP and Drenckhahn D: Role of the endothelial actin filament cytoskeleton in rheology and permeability. Zeitschrift für Kardiologie 78: 1-4, 1989.
12. Nicolson GL and Custead SE: Effects of chemotherapeutic drugs on platelet and metastatic tumor cell-endothelial cell interactions as a model for assessing vascular endothelial integrity. Cancer Res 45: 331-336, 1985.
13. Pettit GR, Singh SB, Niven ML, Hamel E and Schmidt JM: Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Natural Products 50: 119-131, 1987.
14. Hamel E: Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. Pharmac The 55: 31-51, 1992.
15. Jaffe EA, Nachman RL, Becker CG and Minick CR: Culture of human endothelial cells derived from umbilical veins. J Clin Investigation 52: 2745-2756, 1973.
16. Borenfreund E, Babich H and Martin-Alguacil N: Rapid chemosensitivity assay with human normal and tumor cells in vitro. In vitro Cell Dev Biol 26: 1030-1034, 1990.
17. Rosenthal AM and Gotlieb AI: Macrovascular endothelial cells from porcine aorta. In: Cell culture techniques in heart and vessel research (Piper HM ed.), Berlin Heidelberg, Springer-Verlag, 1990, pp. 117-129.
18. Nelson RL, Dyke RW and Root MA: Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treatment Res 7: 17-24, 1980.
19. Machillan WE, Wolberg WH and Welling PG: Pharmacokinetics of fluorourcil in humans. Cancer Res 35: 3479-3482, 1978.
20. Alberts DS, Chang SY, Chen HSG, Evans TL and Moon TE: Oral melphalan kinetics. Cln Pharmacol Ther 26: 737-745, 1979.
21. Albelda SM, Sampson PM, Haselton FR, Mcniff JM, Mueller SN, Williams SK, Fishman AP and Levine EM: Permeability characteristics of cultured endothelial cell monolayers. J Appl Physiol 64: 308-322, 1988.
22. Audus KL, Bartel RL, Hidalgo IJ and Borchardt RT: The use of cultured epithelial and endothelial cells for drug transport and metabolism studies. Pharmaceutical Res 7: 435-451, 1990.
23. Chaplin DJ, Pettit GR, Parkins CS and Hill SA: Antivascular approaches to solid tumour therapy: Evaluation of tubulin binding agents. Brit J Cancer 74: 86-88, 1996.
24. Enomoto T, Okamato T and Sato JD: Vascular endothelial growth factor induces disorganization of actin stress fibers accompanied by protein tyrosine phosphorylation and morphological change in BALB/C3T3 cells. Biochem Biophys Res Comm 202: 1716-1723, 1994.
25. Utoguchi N, Mizuguchi H, Saeki K, Ikeda K, Tsutsumi Y, Nakagawa S and Mayumi T: Tumor-conditioned medium increases macromolecular permeability of endothelial cell monolayer. Cancer Letters 89: 7-14, 1995.